Drugs / Tetanus-Diphtheria Toxoid (Td)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02193347 Background | Jan 2016 → Feb 2020 | brain glioma, primary brain neoplasm | Katy Peters, MD, PhD | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetanus-Diphtheria Toxoid (Td) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02193347 ↗ |
| Modality | Vaccine | “standard of care vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed)” NCT02193347 ↗ |
| Route | Intramuscular | “0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly (I.M.)” NCT02193347 ↗ |